Overview

A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms

Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether a new dosage form and dose of orlistat is equivalent to the currently marketed form.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Orlistat